Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Atrial fibrillation as an acute severity amplifier during cancer hospitalizations: A National Inpatient Sample analysis, 2018–2022.

Christopher Aboujaoude, Sharnvir Chattha, Boone Singtong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23098

e23098 Background: Atrial fibrillation (AF) is highly prevalent among patients with cancer and is frequently treated as a...

Health care utilization and management patterns of asymptomatic incidental pulmonary embolism in cancer patients.

Neha Agrawal, Corbin Edmondson, Corey Jensen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13562

e13562 Background: Asymptomatic incidental pulmonary embolism (iPE) is increasingly detected in cancer patients on routine...

Identification of prognostically relevant residual tumor burden in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs [ <sup>18</sup> F]FET PET.

Jens Blobner, Katharina Müller, Michael Muether et al. Jun 01, 2026 pp. 2068-2068 10.1200/jco.2026.44.16_suppl.2068

2068 Background: Accurate assessment of postoperative residual tumor burden is critical in IDH...

Soluble CD137 in health and disease: A systematic review and meta-analysis.

Sixuan Liu, Yeny Acosta-Ampudia, Carolina Ramírez-Santana et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14528

e14528 Background: Soluble CD137 (sCD137), produced by regulatory T cells, plays a critical role in immune response regula...

RedTail: A next-generation systemic platform for tumor-localized expression of BiTEs and immune activation.

Duong Hoang Nguyen, Yunyi Kang, Stephanie Songco et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14562

e14562 Background: RedTail is a next-generation gene therapy platform engineered for systemic delivery and highly selectiv...

Incidence and survival rates in pediatric and adolescent melanoma in the United States, 2001-2022.

Maimoona Maheen, Aqiba Malik, Mehak Ruqia Jun 01, 2026 pp. 9593-9593 10.1200/jco.2026.44.16_suppl.9593

9593 Background: Melanoma represents a significant malignancy in children, adolescents, and young adults. Recent trends in...

Treatment patterns and outcomes after metastatic recurrence following perioperative chemoimmunotherapy in triple-negative breast cancer (mTNBC).

Riccardo Asnaghi, Carmine Valenza, Nadia Bianco et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13131

e13131 Background: Data on the management and prognosis of metastatic recurrence after perioperative chemoimmunotherapy in...

Global burden of stomach cancer attributable to alcohol use (1990-2023): A comprehensive epidemiological analysis.

Mandeepsinh Vashi, Kashish Magnani, Ibrahim Balogun et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16361

e16361 Background: Alcohol consumption is a Group 1 carcinogen by the International Agency for Research on Cancer, yet its...

Turning clinically approved PARP inhibitors into immunotherapy sensitizers by reprogramming the tumor microenvironment in colorectal cancer.

Mai M. Abouzeid, Mohamed Ghonim, Hamid Boulares Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14552

e14552 Background: PARP1 promotes tumor survival through compensatory DNA-repair pathways and inflammatory signaling. Whil...

Inpatient outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the United States, 2018–2023.

Arash Latifi, Faizan Sheraz, Arman Manjikian et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15605

e15605 Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is a highly complex on...

The association of lymph node yield and survival after neoadjuvant immunotherapy for head and neck cancer: An NCDB analysis.

Jenny Kim, Micah Harris, Katie M. Carlson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18120

e18120 Background: Comprehensive lymph node resection is a quality measure previously associated with survival for head an...

Adjuvant antibody-drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): A US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations.

Paolo Tarantino, Thibaut Sanglier, Elsa Garcia Hernandez et al. Jun 01, 2026 pp. 535-535 10.1200/jco.2026.44.16_suppl.535

535 Background: The KATHERINE trial established adjuvant T-DM1 as standard of care (SoC) treatment for patients with HER2+...

Connectome-sparing stereotactic radiosurgery: Results from the phase II COG-SRS trial.

Andrew Connor Puett, Jiwandeep Kohli, Roshan Huynh Karunamuni et al. Jun 01, 2026 pp. 2002-2002 10.1200/jco.2026.44.16_suppl.2002

2002 Background: Cognitive decline remains common after radiosurgery. The cognition-sparing stereotactic radiosurgery tria...

Real-world brain metastasis outcomes with T-DXd versus tucatinib-based therapy in second-line HER2-positive metastatic breast cancer.

Zunairah Shah, Han Yu, Safa Saadat Afridi et al. Jun 01, 2026 pp. 1051-1051 10.1200/jco.2026.44.16_suppl.1051

1051 Background: Brain metastases (BM) remain a major cause of morbidity and mortality in HER2+ metastatic breast cancer (...

Synergistic efficiency of methylene blue and carbon nanoparticles for sentinel lymph node biopsy in early breast cancer: A large-scale real-world cohort study of 1,355 patients.

Hongjin Liu, Jingming Ye Jun 01, 2026 pp. 583-583 10.1200/jco.2026.44.16_suppl.583

583 Background: Sentinel lymph node biopsy (SLNB) using radioisotopes and fluorescence imaging is the gold standard but re...

Variants of uncertain significance and contralateral risk-reducing mastectomy in early-stage breast cancer across safety-net and private hospital settings.

Vineeth Reddy Kommidi, Diti Patel, Ang Gao et al. Jun 01, 2026 pp. 10603-10603 10.1200/jco.2026.44.16_suppl.10603

10603 Background: Germline genetic testing informs surgical decisions in early-stage breast cancer. Guidelines recommend c...

A systematic review and meta-analysis of artificial intelligence–assisted colon capsule endoscopy for colorectal polyp detection.

Raj Nandan Chennuri, Adithya Chandran, Hrishikesh Kommu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15520

e15520 Background: Colorectal cancer remains a leading cause of cancer-related mortality worldwide, with early polyp detec...

Histology-dependent survival and treatment benefit in primary tracheal cancer: A population-based analysis.

Chinemerem MARTLIN Emeasoba, Chiugo Okoye, Chidi Obialo-Ibeawuchi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23386

e23386 Background: Primary tracheal cancer is a rare thoracic malignancy representing only 0.1-0.4% of all malignancies. E...

HER2 discordance in upper gastrointestinal cancers in a US-based analysis.

Brandon Edward Rose, Udhayvir Singh Grewal, Peifeng Ruan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16086

e16086 Background: HER2 overexpression is present in 20 to 30% of advanced upper gastrointestinal (UGI) cancers and can be...

Tobacco use–driven lung cancer mortality in the United States: A population-based analysis from 2003 to 2023.

Dhivya Bharathi Govindaraj, Mohammed Shahzebuddin Baag, Vishan Das et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20039

e20039 Background: Lung cancer (LC) is the leading cause of cancer death worldwide, with tobacco use as its primary risk f...

Temporal trends and racial disparities in cancer-related mortality among individuals with substance use involvement in the United States, 1999–2023.

Arwaa Chaudhry, Muaz Ahmed Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22630

e22630 Background: Cancer-related mortality associated with substance use is an increasing public health concern in the Un...

Features of the content of components of the vascular endothelial growth factor system in the blood of men with recurrent soft tissue sarcomas.

Pavel V. Chernogorov, Irina V. Kaplieva, Elena M. Frantsiyants et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23550

e23550 Background: Soft tissue sarcomas (STS) have been studied to a lesser extent than tumors of epithelial origin. The m...

Neoadjuvant radiotherapy combined with lenvatinib and sintilimab in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus: An open-label, single-arm, multicenter, prospective phase I clinical trial.

Bin Shu, Guangxin Li, Yang Xiong et al. Jun 01, 2026 pp. 4113-4113 10.1200/jco.2026.44.16_suppl.4113

4113 Background: Surgical resection remains the potentially curative treatment for resectable hepatocellular carcinoma (HC...

Expression of nectin-4 in germ-cell tumors.

Tareq Salous, George Sandusky, Noah Richardson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17009

e17009 Background: Nectin-4 is a cell adhesion molecule and therapeutic target in several malignancies, including urotheli...

Development of a point-of-care clinical decision support system to optimize total cost of care, while preserving quality outcomes: Integration of economic, clinical, pathological, genomic data, and national guidelines.

Andrew L. Pecora, Christopher C. Windham Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23301

e23301 Background: Rising cancer care costs challenge patients and policymakers, with approximately 80% of expenditures dr...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page